NFE2L2 and hepatocellular carcinoma: Treatment with DMC caused decreased expression of NRF2 and blocked its nuclear translocation as well as its binding to AREs, resulting in decreased levels of GSH in human hepatocellular carcinoma BEL-7402/5-FU cells [4,65,66].